Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia

• Main Authors: Daniel-Spiegel Etty (Author), Goldman Shlomit (Author), Lavee Michal (Author), Shalev Eliezer (Author)
• Format: Book
• Published: BMC, 2009-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

<p>Abstract</p> <p>Objective</p> <p>To evaluate levels of matrix metalloproteinases (MMP) and their inhibitors (TIMP) in second trimester amniotic fluid of women with hypertensive disorders compared to normotensive women.</p> <p>Study Design</p> <p>Amniotic fluid was obtained from 133 women undergoing genetic second trimester amniocentesis. Zymography was performed for MMP characterization and an MMP-2 ELISA kit was used to determine MMP-2 levels. TIMP-2 expression was evaluated using western blot.</p> <p>Results</p> <p>Mean amniotic fluid MMP-2 and TIMP-2 levels were significantly higher in women who developed a hypertensive disorder compared to normotensive women (P < 0.0004 and P < 0.01, respectively). When subdivided into subgroups, amniotic fluid from women who eventually developed preeclampsia or superimposed preeclampsia showed significantly higher MMP-2 levels than normotensive women (P < 0.05). However, no statistical difference in MMP-2 levels was found between patients with gestational hypertension and normotensive patients.</p> <p>Conclusion</p> <p>Higher amniotic fluid MMP-2 and TIMP-2 levels are found in women who eventually develop preeclampsia.</p>

Item Description

10.1186/1477-7827-7-85
1477-7827